Clinical Trial Update: Developing Oral LT3 Therapy for Heart Failure - HFpEF [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating oral liothyronine (LT3) for heart failure with preserved ejection fraction and low T3 syndrome has completed, with results posted Jan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Low T3 Syndrome

Drugs mentioned

• Liothyronine (liothyronine)

Snippet

Sponsor: University of Pennsylvania | Conditions: Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-01-08